US4684649A - Quinoxaline derivatives useful for treatment and prophylaxis of swine dysentery and as animal growth promotants - Google Patents

Quinoxaline derivatives useful for treatment and prophylaxis of swine dysentery and as animal growth promotants Download PDF

Info

Publication number
US4684649A
US4684649A US06/825,643 US82564386A US4684649A US 4684649 A US4684649 A US 4684649A US 82564386 A US82564386 A US 82564386A US 4684649 A US4684649 A US 4684649A
Authority
US
United States
Prior art keywords
compound
quinoxaline
dioxide
phenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US06/825,643
Inventor
Enrico Marotta
Lucia Castronuovo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of US4684649A publication Critical patent/US4684649A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • This invention relates to quinoxaline derivatives which are useful antiinfective agents for the control of various pathogenic microorganisms and as animal growth promotants.
  • animal infectious diseases caused by pathogenic microorganisms which can be controlled by the compounds of the present invention there are the following ones: chronic respiratory disease in poultry, infectious sinusities in turkeys, and, especially swine dysentery.
  • Swine dysentery is a severe mucohemmorrhagic diarrheal disease that primarily affects pigs during the growing-finishing period. Swine dysentery occurs in most swinerearing areas of the world.
  • the primary etiologic agent of swine dysentery is an anaerobic spirochete called Treponema hyodysenteriae.
  • the compounds of the present invention display a marked reduction in these untoward effects, and they may, therefore, be used with a higher degree of safety or in larger amounts for a quicker control of various pathogenic microorganisms and for the acceleration of animal growth rate and for improved feed efficiency.
  • Object of the present invention is therefore a new series of 2-[bis(1'-hydroxy-4'-methoxy-phenyl 2')-methyl]-quinoxaline-1,4-dioxide derivatives of the structural formula I ##STR2## wherein the two substituents R on the phenyl rings are equal or different and represents C 1 -C 5 lower alkyl, preferably t-butyl- and R 1 is a 6- or 7-position substituent selected from the group consisting of hydrogen, halogen, lower alkyl, lower alkoxy and lower alkanoyl.
  • lower alkyl, lower alkoxy, and lower alkanoyl are meant those groups which contain from 1 to 4 carbon atoms, i.e. those which are conveniently prepared from readily available starting materials.
  • the compound of this invention of formula I may be prepared by reacting 2 moles of a suitable phenoxy magnesium halide derivative of structure II with 1 mole of a 2-formyl-quinoxaline-1,4-dioxide of formula III ##STR3## wherein R and R 1 have the above meaning, and X is Cl or Br.
  • reaction is carried out in an anhydrous apolar organic solvent such benzene, toluene or xylene under nitrogen atmosphere.
  • the reaction starts at room temperature, but it is preferred to complete it at warm temperature, preferably at the boiling temperature of the solvent employed.
  • the time reaction may vary from a few minutes to several hours according to the reaction employed.
  • the molar ratio between the phenoxy magnesium halide derivative II and the 2-formyl-quinoxaline-1,4-dioxide derivative III is 2:1, but it is preferred to use a slight excess of II.
  • the phenoxy magnesium halide II generally chloride or bromide must be prepared separately according to known methods usually employed in the Grignard reactions.
  • Preferred compounds of the present invention are those in which R 1 is hydrogen, and those in which both substituents R on the phenyl ring are t-butyl.
  • the preferred compound is that in which R 1 is hydrogen and the t-butyl substituent is located at the ortho-position with respect to the methoxy-group in the phenyl ring.
  • the compounds of the present invention are generally white-yellow crystalline powder, almost tasteless or slightly bitter.
  • these compounds When administered at pharmaceutically effective dosage levels, these compounds are antibacterial agents useful in animal health care. They have been found to cure some infectious diseases in animals such as poultry goats, sheep, horses, cattle and swine.
  • the novel compounds of the present invention exhibit excellent activity against swine salmonellosis and in particular against swine dysentery caused by Treponema hyodysenteriae.
  • novel compounds of the present invention have shown to be completely free from any mutagenic effect according to the "Ames test" (B.N. Ames et al - Mutation Research 31, page 347, 1975).
  • the compounds of the present invention are effective animal growth promotants particularly for swine and poultry. The animals thus attain market size sooner and on less feed.
  • MIC's against Treponema hyodysenteriae were determined by spreading appropriate dilutions of the microorganism on a growth medium containing about 5% bovine blood and about 3% tryptose agar.
  • the numbers in the right column with respect to R and R 1 indicate the position of the substituent in the phenyl and quinoxaline rings, respectively.
  • Acute systemic infections in mice have been used to evaluate the in vivo therapeutic activity of compound of Example 1.
  • ED 50 i.e. the dose of the compound in mg/Kg body weight required to protect 50% of the treated animals against otherwise lethal infections.
  • the compounds were administered both orally and subcutaneously. The results are given below.
  • the compound of the present invention may be administered orally or parenterally.
  • the compounds When administered orally for prophylactic purposes, the compounds are usually blended into a nutritionally balanced feed at a level of one to 300 grams per ton. For therapeutic purposes higher dosage levels may be employed. Typical nutritionally balanced feed for hogs are shown in the table below.
  • the toxicity of the compounds of the present invention is very low: in the rat the LD 50 is 600 mg/kg b.w. by intraperitoneal route and more than 5000 mg/kg b.w. by oral route.
  • the compound is soluble in dimethylformamide, tetrahydrofuran and dioxane. It is slightly soluble in benzene, acetone, methanol. It is very scarcely soluble in water. Heated above 150° C. it decomposes without melting.
  • Example 1 Compound of Example 1 was mixed with the swine balanced feed described on page 8 at the ratio of 200 grams/ton. A group of 30 pigs was fed with this medicated diet. An equivalent group of pigs was used as control. The two groups were stabled in pigsties where infections of Treponema hyodysenterae have been observed. No one of the animals under treatment was getting ill, while the 50% of the untreated animals in the control group was clearly showing typical symptoms of swine dysentery. The infected animals recovered completely after 2 weeks of treatment with the above mentioned medicated feed.
  • Example 1 The efficacy of compound of Example 1 in promoting growth and improving the feed efficiency is illustrated below. 20 healthy pigs of same age and of average same weight were divided into two groups. One group of 10 pigs served as control and was fed a basal non-supplemented diet, the other group of 10 pigs received the same basal diet, but supplemented with 200 grams/ton of compound of Example 1.
  • the pigs on the supplemented diet are, on the average, 4,6% heavier than the pigs which received the control ration and demonstrated a 5,5% increase in feed efficiency over the controls.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)

Abstract

The present invention concerns quinoxaline derivatives of the structural formula I: ##STR1## wherein the two substituents R on the phenyl rings are equal or different and represents C1 -C5 lower alkyl, and R1 is a 6- or 7-position substituent selected from the group consisting of hydrogen, halogen, lower alkyl, lower alkoxy and lower alkanoyl.
Such compounds have been found useful in preventing swine dysentery as well as being used as animal growth promotants.

Description

This invention relates to quinoxaline derivatives which are useful antiinfective agents for the control of various pathogenic microorganisms and as animal growth promotants. Among the animal infectious diseases caused by pathogenic microorganisms which can be controlled by the compounds of the present invention there are the following ones: chronic respiratory disease in poultry, infectious sinusities in turkeys, and, especially swine dysentery. Swine dysentery is a severe mucohemmorrhagic diarrheal disease that primarily affects pigs during the growing-finishing period. Swine dysentery occurs in most swinerearing areas of the world. The primary etiologic agent of swine dysentery is an anaerobic spirochete called Treponema hyodysenteriae.
Various analogs of the compounds of the present invention are known in the prior art to be useful for such purposes. Typical examples of these prior art analogs are disclosed in U.S. Pat. Nos. 3,344,022; 3,371,090; 3,558,624; 4,086,345; 4,128,642.
Whereas these prior art analogs showed useful activity for the stated purposes, it has been found that they display certain toxic side effects. For example 2-formyl-quinoxaline-1,4-dioxide carbomethoxyhydrazone disclosed and claimed in the above mentioned U.S. Pat. No. 3,371,090 and with the generic name carbadox has proved to exhibit a substantial mutagenic effect. This effect of chemotherapeutic active substances is conveniently determined according to the "Ames test" (B.N. Ames et al. Mutation Research 31, page 347, 1975).
Unexpectedly, it has been found that the compounds of the present invention display a marked reduction in these untoward effects, and they may, therefore, be used with a higher degree of safety or in larger amounts for a quicker control of various pathogenic microorganisms and for the acceleration of animal growth rate and for improved feed efficiency. Object of the present invention is therefore a new series of 2-[bis(1'-hydroxy-4'-methoxy-phenyl 2')-methyl]-quinoxaline-1,4-dioxide derivatives of the structural formula I ##STR2## wherein the two substituents R on the phenyl rings are equal or different and represents C1 -C5 lower alkyl, preferably t-butyl- and R1 is a 6- or 7-position substituent selected from the group consisting of hydrogen, halogen, lower alkyl, lower alkoxy and lower alkanoyl.
By the terms lower alkyl, lower alkoxy, and lower alkanoyl are meant those groups which contain from 1 to 4 carbon atoms, i.e. those which are conveniently prepared from readily available starting materials.
The compound of this invention of formula I may be prepared by reacting 2 moles of a suitable phenoxy magnesium halide derivative of structure II with 1 mole of a 2-formyl-quinoxaline-1,4-dioxide of formula III ##STR3## wherein R and R1 have the above meaning, and X is Cl or Br.
The reaction is carried out in an anhydrous apolar organic solvent such benzene, toluene or xylene under nitrogen atmosphere.
The reaction starts at room temperature, but it is preferred to complete it at warm temperature, preferably at the boiling temperature of the solvent employed. The time reaction may vary from a few minutes to several hours according to the reaction employed. The molar ratio between the phenoxy magnesium halide derivative II and the 2-formyl-quinoxaline-1,4-dioxide derivative III is 2:1, but it is preferred to use a slight excess of II.
When the reaction is over the solution is cooled to room temperature and it is neutralized with a dilute aqueous inorganic acid such hydrochloric or sulfuric acid.
The organic layer is separated, washed and evaporated "in vacuo" to dryness. The residue is then purified by crystallization.
The phenoxy magnesium halide II, generally chloride or bromide must be prepared separately according to known methods usually employed in the Grignard reactions. The desired phenol derivative of structure: ##STR4## wherein R has the above meaning, dissolved in an anhydrous linear or cyclic ether such as ethyl ether, tetrahydrofuran or dioxane is added at room temperature to an equimolecular solution of methyl- or ethyl-magnesium chloride or bromide in ethyl ether.
This solution of methyl- or ethyl-magnesium chloride or bromide was previously prepared and kept under nitrogen. After formation of the desired phenoxy magnesium halide II, most part of the ether solvent is removed by distillation under reduced pressure of nitrogen.
Always under nitrogen atmosphere anhydrous benzene or toluene is cautiously added.
The 2-formyl-quinoxaline-1,4-dioxide derivative III also dissolved in anhydrous benzene or toluene is now added dropwise with stirring and allowed to react as indicated above.
Preferred compounds of the present invention are those in which R1 is hydrogen, and those in which both substituents R on the phenyl ring are t-butyl.
The preferred compound is that in which R1 is hydrogen and the t-butyl substituent is located at the ortho-position with respect to the methoxy-group in the phenyl ring.
The compounds of the present invention are generally white-yellow crystalline powder, almost tasteless or slightly bitter.
They are soluble in dimethylformamide and tetrahydrofuran, slightly soluble in aromatic hydrocarbon, acetone and lower alcohols, and they are sparingly or almost insoluble in water.
When administered at pharmaceutically effective dosage levels, these compounds are antibacterial agents useful in animal health care. They have been found to cure some infectious diseases in animals such as poultry goats, sheep, horses, cattle and swine. The novel compounds of the present invention exhibit excellent activity against swine salmonellosis and in particular against swine dysentery caused by Treponema hyodysenteriae.
As briefly mentioned above the novel compounds of the present invention have shown to be completely free from any mutagenic effect according to the "Ames test" (B.N. Ames et al - Mutation Research 31, page 347, 1975). In addition the compounds of the present invention are effective animal growth promotants particularly for swine and poultry. The animals thus attain market size sooner and on less feed.
The in vitro broad spectrum antibacterial activity of these compounds is demonstrated by determining minimum inhibitory concentration (MIC).
MIC's against Treponema hyodysenteriae were determined by spreading appropriate dilutions of the microorganism on a growth medium containing about 5% bovine blood and about 3% tryptose agar.
Among the compounds of structure I subjected to in vitro screening were the following in which R and R1 have the above meaning.
The numbers in the right column with respect to R and R1 indicate the position of the substituent in the phenyl and quinoxaline rings, respectively.
__________________________________________________________________________
Compound of Example                                                       
            R    R.sub.1                                                  
                   mp.(C) MIC (μg/ml)                                  
                                 Position of R/R.sub.1 Substituent on     
__________________________________________________________________________
                                 Ring                                     
1           t-butyl                                                       
                 H 150° C. dec.                                    
                          0,1    3'/--                                    
2           i-propyl                                                      
                 H 175    0,9    3'/--                                    
__________________________________________________________________________
Acute systemic infections in mice have been used to evaluate the in vivo therapeutic activity of compound of Example 1.
These infections are produced by the intraperitoneal injection of standard cultures suspended in hog gastrin mucin. Half an hour after inoculation the treatment was set up. Efficacy may be measured in ED50 i.e. the dose of the compound in mg/Kg body weight required to protect 50% of the treated animals against otherwise lethal infections. The compounds were administered both orally and subcutaneously. The results are given below. The compound of the present invention may be administered orally or parenterally.
When administered orally for prophylactic purposes, the compounds are usually blended into a nutritionally balanced feed at a level of one to 300 grams per ton. For therapeutic purposes higher dosage levels may be employed. Typical nutritionally balanced feed for hogs are shown in the table below.
______________________________________                                    
                Kg. per ton of feed                                       
______________________________________                                    
Ground Corn       956.000                                                 
Dicalcium phosphate                                                       
                  12.900                                                  
Calcium carbonate 14.900                                                  
Mixture of vitamins A,D                                                   
                  3.240                                                   
niacin, calcium pantothenate                                              
Choline           3.240                                                   
Mineral salts     3.240                                                   
Inorganic iodides 6.480                                                   
______________________________________
Toxicity
The toxicity of the compounds of the present invention is very low: in the rat the LD50 is 600 mg/kg b.w. by intraperitoneal route and more than 5000 mg/kg b.w. by oral route.
The following Examples are solely for the purpose of illustration only and are not to be construed as limitations of this invention.
EXAMPLE 1 2-[bis(1'-hydroxy-3'-t-butyl-4'-methoxy-phenyl-2')-methyl]-quinoxaline-1,4-dioxide
A solution of 360 g of 3-t-butyl-4-methoxyphenol (2 mol) in 1000 ml of anhydrous peroxide-free tetrahydrofuran was purged of atmospheric oxygen by bubbling nitrogen therethrough for about three minutes. To this solution cooled to 0° C. a solution of 2 mol of methyl-magnesium-bromide in 1200 ml of anhydrous tetrahydrofuran previously prepared under nitrogen was added over 20 minutes with stirring. Most of the tetrahydrofuran was removed by distillation under nitrogen. Then 4000 ml of anhydrous benzene were added. A solution of 190 g of 2-formyl-quinoxaline-1,4-dioxide (1 mol) in 1000 ml of anhydrous benzene was added to the previous solution under nitrogen with stirring. Stirring was continued at room temperature overnight and then the reaction mixture was heated with stirring under reflux for 1 hour. After cooling to room temperature the mixture was poured into a suitable separatory funnel and neutralized with 10% aqueous hydrochloric acid and thoroughly shaken. The organic layer was separated, washed and evaporated "in vacuo" to dryness. The residue was recrystallized from acetone.
280 g of purified compound were obtained. PMR and IR spectrum confirmed the expected structure. Empirical formula: C31 H36 N2 O6.
______________________________________                                    
            Calculated                                                    
                    Found                                                 
______________________________________                                    
% C           69,92     69,95                                             
% H            6,76      6,80                                             
% O           18,04     17,98                                             
% N            5,26      5,30                                             
______________________________________
The compound is soluble in dimethylformamide, tetrahydrofuran and dioxane. It is slightly soluble in benzene, acetone, methanol. It is very scarcely soluble in water. Heated above 150° C. it decomposes without melting.
Comparable result was achieved when methyl-magnesium-chloride was used instead of methyl magnesium bromide.
EXAMPLE 2 2-[bis(1'-hydroxy-3'-i-propyl-4'-methoxy-phenyl-2')-methyl]-quinoxaline-1,4-dioxide
By operating according to the method described in Example 1 but by replacing 3-t-butyl-4-methoxy-phenol with 3-i-propyl-4-methoxy-phenol, the title compound was obtained (m.p. 175° C. with decomposition).
EXAMPLE 3 2-[bis(1'-hydroxy-3'-ethyl-4'-methoxy-phenyl-2')-methyl]-quinoxaline-1,4-dioxide
By operating according to the method described in Example 1 but by replacing 3-t-butyl-4-methoxy-phenol with 3-ethyl-4-methoxy-phenol, the title compound was obtained (m.p. 189° C. with decomposition).
EXAMPLE 4 2-[bis(1'-hydroxy-3'-t-butyl-4'methoxy-phenyl-2')-methyl]-6-chloro-quinoxaline-1,4-dioxide
By operating according to the method described in Example 1, but by replacing 2-formyl-quinoxaline-1,4-dioxide with 2-formyl-6-chloro-quinoxaline-1,4-dioxide the title compound was obtained.
EXAMPLE 5 2-[bis(1'-hydroxy-3'-t-butyl-4'-methoxy-phenyl-2')-methyl]-6-methyl-quinoxaline-1,4-dioxide
By operating according to the method described in Example 1, but by replacing 2-formyl-quinoxaline-1,4-dioxide with 2-formyl-6-methyl-quinoxaline-1,4-dioxide the title compound was obtained.
EXAMPLE 6
Compound of Example 1 was mixed with the swine balanced feed described on page 8 at the ratio of 200 grams/ton. A group of 30 pigs was fed with this medicated diet. An equivalent group of pigs was used as control. The two groups were stabled in pigsties where infections of Treponema hyodysenterae have been observed. No one of the animals under treatment was getting ill, while the 50% of the untreated animals in the control group was clearly showing typical symptoms of swine dysentery. The infected animals recovered completely after 2 weeks of treatment with the above mentioned medicated feed.
EXAMPLE 7
The efficacy of compound of Example 1 in promoting growth and improving the feed efficiency is illustrated below. 20 healthy pigs of same age and of average same weight were divided into two groups. One group of 10 pigs served as control and was fed a basal non-supplemented diet, the other group of 10 pigs received the same basal diet, but supplemented with 200 grams/ton of compound of Example 1.
After 28 days treatment, the pigs on the supplemented diet are, on the average, 4,6% heavier than the pigs which received the control ration and demonstrated a 5,5% increase in feed efficiency over the controls.
EXAMPLE 8 Mutation Test determined according to the "Ames test" (B.N. Ames et al. Mutation Research 31, page 347, 1975).
The compound 2-[bis-(1'-hydroxy-3'-t-butyl-4'-methoxy-phenyl-2')-methyl-quinoxaline-1,4-dioxide prepared according to Example 1 was submitted to the Ames test showing the results summarized in the following two tables:
              TABLE 1                                                     
______________________________________                                    
(in the absence of microsomial extract)                                   
              Number of mutating colonies/plate                           
Quantity      with strains of Salmonella Typhimurium                      
(in mcg)      TA 1538  TA 1535   TA 98 TA 100                             
______________________________________                                    
of the tested compound                                                    
 0            31       28        24    164                                
 10           11       15        25    168                                
 30           16       12        24    165                                
100           15        9        27    151                                
300           10       13        24    162                                
600           17       25        27    177                                
1000          17       16        27    142                                
of sodium azide                                                           
 10           --       1006      --    --                                 
______________________________________                                    

              TABLE 2                                                     
______________________________________                                    
(in the presence of microsomial extract)                                  
              Number of mutating colonies/plate                           
Quantity      with strains of Salmonella Typhimurium                      
(in mcg)      TA 1538  TA 1535   TA 98 TA 100                             
______________________________________                                    
of the tested compound                                                    
 0            28       28        29    163                                
 10           16       23        30    158                                
 30           14       26        27    143                                
100           15       22        24    135                                
300            8       16        20    174                                
600           18       22        24    175                                
1000          14       20        28    125                                
of sodium azide                                                           
 10           2258     --        1803  --                                 
______________________________________

Claims (8)

What is claimed is:
1. A compound of the structure I: ##STR5## wherein the two substituents R on the phenyl rings are equal or different and represents C1 -C5 lower alkyl, and R1 is a 6- or 7-position substituent selected from the group consisting of hydrogen, halogen, C1 -C4 lower alkyl, C1 -C4 lower alkoxy and C1 -C4 lower alkanoyl.
2. A compound of claim 1 which is 2-[bis(1'-hydroxy-3'-t-butyl-4'-methoxy-phenyl-2')-methyl]-quinoxaline-1,4-dioxide.
3. A compound of claim 1 which is 2-[bis(1'-hydroxy-3'-i-propyl-4'-methoxy-phenyl-2')-methyl]-quinoxaline-1,4-dioxide.
4. A compound of claim 1 which is 2-[bis(1'-hydroxy-3'-ethyl-4'-methoxy-phenyl-2')-methyl]-quinoxaline-1,4-dioxide.
5. A method of controlling swine dysentery which comprises administering to said animals a pharmaceutically effective amount of a compound of claim 1.
6. A method of promoting growth and improving feed efficiency of animals which comprises administering to said animals a pharmaceutically effective amount of a compound of claim 1.
7. An animal feed composition which comprises a nutritionally balanced animal feed containing a compound of claim 1 in the ratio from 1 to 300 g per ton of feed.
8. An animal feed composition according to claim 7 in which the compound is 2-[bis(1'-hydroxy-3'-t-butyl-4'-methoxy-phenyl-2')-methyl]-quinoxaline-1,4-dioxide.
US06/825,643 1985-03-01 1986-02-03 Quinoxaline derivatives useful for treatment and prophylaxis of swine dysentery and as animal growth promotants Expired - Fee Related US4684649A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8505286 1985-03-01
GB08505286A GB2171693A (en) 1985-03-01 1985-03-01 Quinoxaline derivatives useful for treatment and prophylaxis of swine dysentry and as animal growth promotants

Publications (1)

Publication Number Publication Date
US4684649A true US4684649A (en) 1987-08-04

Family

ID=10575271

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/825,643 Expired - Fee Related US4684649A (en) 1985-03-01 1986-02-03 Quinoxaline derivatives useful for treatment and prophylaxis of swine dysentery and as animal growth promotants

Country Status (9)

Country Link
US (1) US4684649A (en)
EP (1) EP0192992A3 (en)
JP (1) JPS61205263A (en)
CN (1) CN86101225A (en)
AU (1) AU575467B2 (en)
CA (1) CA1245652A (en)
DK (1) DK89686A (en)
GB (1) GB2171693A (en)
HU (1) HU195787B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103664807A (en) * 2013-12-02 2014-03-26 河北美荷药业有限公司 3-methyl-2-(methoxy styrene keto)-quinoxaline-1,4-dioxide, and preparation method and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1041011A (en) * 1962-04-12 1966-09-01 Fisons Pest Control Ltd Fungicidal compositions and halogenated quinoxalines
US3344022A (en) * 1964-08-31 1967-09-26 Pfizer & Co C Method of treating chronic respiratory disease in poultry
US3474097A (en) * 1967-04-03 1969-10-21 Pfizer & Co C Preparation of quinoxaline-n,n'-dioxides
US3816630A (en) * 1972-02-08 1974-06-11 Ici Ltd Treatment of swine dysentery
US4086345A (en) * 1976-03-31 1978-04-25 Istituto Chemioterapico Italiano Product and method for combatting swine dysentery
US4634702A (en) * 1983-11-07 1987-01-06 Daniele Gatti Quinoxalinemethanol compounds for combatting swine dysentery and as growth promoting factors, method of preparation, and compositions containing them

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4012385A (en) * 1975-08-06 1977-03-15 Pfizer Inc. Antibacterial quinoxaline 1,4-dioxides
NZ194196A (en) * 1979-07-17 1983-07-15 Ici Australia Ltd -(quinoxalin-2-yl(oxy or thio) phen (oxy or ylthio)-alkanoic acid derivatives or precursors
AU547454B2 (en) * 1981-01-12 1985-10-24 Ici Australia Limited 2-phenoxyguinoxelines
AU542299B2 (en) * 1981-09-11 1985-02-14 Egyt Gyogszervegyeszeti Gyar 2-hydroxymethyl-quinoxaline-1, 4-dioxide derivatives, a process for preparing same and compositions containing same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1041011A (en) * 1962-04-12 1966-09-01 Fisons Pest Control Ltd Fungicidal compositions and halogenated quinoxalines
US3344022A (en) * 1964-08-31 1967-09-26 Pfizer & Co C Method of treating chronic respiratory disease in poultry
US3474097A (en) * 1967-04-03 1969-10-21 Pfizer & Co C Preparation of quinoxaline-n,n'-dioxides
US3816630A (en) * 1972-02-08 1974-06-11 Ici Ltd Treatment of swine dysentery
US4086345A (en) * 1976-03-31 1978-04-25 Istituto Chemioterapico Italiano Product and method for combatting swine dysentery
US4634702A (en) * 1983-11-07 1987-01-06 Daniele Gatti Quinoxalinemethanol compounds for combatting swine dysentery and as growth promoting factors, method of preparation, and compositions containing them

Also Published As

Publication number Publication date
AU575467B2 (en) 1988-07-28
GB2171693A (en) 1986-09-03
HU195787B (en) 1988-07-28
AU5389386A (en) 1986-09-04
HUT40089A (en) 1986-11-28
EP0192992A3 (en) 1987-08-12
JPS61205263A (en) 1986-09-11
CA1245652A (en) 1988-11-29
CN86101225A (en) 1986-09-03
DK89686A (en) 1986-09-02
GB8505286D0 (en) 1985-04-03
DK89686D0 (en) 1986-02-27
EP0192992A2 (en) 1986-09-03

Similar Documents

Publication Publication Date Title
US3912723A (en) 2-Phenyl-as-triazine-3,5(2H,4H)diones
KR20060111605A (en) Florfenicol prodrug with improved water solubility
EP0087218B1 (en) Guanidine derivatives
US3528985A (en) Benzoylethyl quaternary ammonium compounds as anthelmintic agents
US4225604A (en) 2-Formylquinoxaline-1,4-dioxide cyanoacetylhydrazone and methods for preparation thereof
US3493572A (en) Process for producing quinoxaline-di-n-oxides
US4423050A (en) 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent
US4684649A (en) Quinoxaline derivatives useful for treatment and prophylaxis of swine dysentery and as animal growth promotants
US3560496A (en) 2-benzyl-as-triazine-3,5(2h,4h) diones
EP0098589B1 (en) Quinazoline derivatives which are active against coccidiosis
US4476138A (en) 1-Methyl-5-nitro-(2-substituted)-2H-imidazole derivatives, and use as bactericidal and protozoacidal agents
US3901944A (en) 1,3-bis(substituted benzylideneamino)guanidines
US3966951A (en) Esters of quinoxaline-1,4-dioxides
IL32213A (en) Substituted guanidines
US4603219A (en) 1,3-dibenzyloxy-2-acetoxymethoxypropane, intermediate for 9-(1,3-dihydroxy-2-propoxymethyl)guanine
EP0101951A1 (en) 1,3-Dioxolo(4,5-g)quinolines and preparation thereof
US3948911A (en) Substituted quinoxaline-2-carboxamide 1,4-dioxides
US4007184A (en) Substituted alkyl esters of quinoxaline-di-N-oxide-2-carboxylic acid
US4267191A (en) Process for enhancing growth promotion in animals
US3767657A (en) Process for the preparation of quinoxaline di n oxides
US3907994A (en) Substituted alkyl esters quinoxaline-di-N-oxide-2-carboxylic acid as growth promoting agents
US3991053A (en) Antibacterial 1,3-dihydrofuro[3,4-b]quinoxaline 4,9-dioxides
SU1186616A1 (en) Quinoxaline-1,4-dioxide derivatives possessing ability to gain increase in weight of animals
US4568694A (en) Growth-enhancing cystamine derivatives
CS226038B2 (en) Method of preparing 2-hydromethylquinoxaline-1,4-dioxide derivatives

Legal Events

Date Code Title Description
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 19910804